Company profile STOK
There is not enough data for Stoke Therapeutics -biotechnology to provide analysis
There is not enough data for Stoke Therapeutics -biotechnology to provide correlation calculation
There is not enough data for Stoke Therapeutics -biotechnology to provide analysis
There is not enough data for Stoke Therapeutics login to provide analysis
There is not enough data for Stoke Therapeutics login to provide correlation calculation
There is not enough data for Stoke Therapeutics login to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Stoke Therapeutics stock expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 61 | 202 231.1% QoQ | 101 -50.0% QoQ | 261 158.4% QoQ |
| 2020 | 246 303.3% YoY -5.7% QoQ | 101 -50.0% YoY -58.9% QoQ | 238 135.6% YoY 135.6% QoQ | 270 3.4% YoY 13.4% QoQ |
| 2021 | 105 -57.3% YoY -61.1% QoQ | 294 191.1% YoY 180.0% QoQ | 31 -87.0% YoY -89.5% QoQ | 139 -48.5% YoY 348.4% QoQ |
| 2022 | 51 -51.4% YoY -63.3% QoQ | 147 -50.0% YoY 188.2% QoQ | 18 -41.9% YoY -87.8% QoQ | 78 -43.9% YoY 333.3% QoQ |
| 2023 | 139 172.5% YoY 78.2% QoQ | 121 -17.7% YoY -12.9% QoQ | 242 1244.4% YoY 100.0% QoQ | 100 28.2% YoY -58.7% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Stoke Therapeutics stock was 11.28 per week. The last year interest of Stoke Therapeutics stock compared to the last 5 years has changed by -8.24%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -28.42%.
There is not enough data for Stoke Therapeutics CEO to provide analysis
There is not enough data for Stoke Therapeutics CEO to provide correlation calculation
There is not enough data for Stoke Therapeutics CEO to provide analysis
There is not enough data for Stoke Therapeutics address to provide analysis
There is not enough data for Stoke Therapeutics address to provide correlation calculation
There is not enough data for Stoke Therapeutics address to provide analysis
There is not enough data for STK-002 clinical trial to provide analysis
There is not enough data for STK-002 clinical trial to provide correlation calculation
There is not enough data for STK-002 clinical trial to provide analysis
There is not enough data for autosomal dominant optic atrophy treatment to provide analysis
There is not enough data for autosomal dominant optic atrophy treatment to provide correlation calculation
There is not enough data for autosomal dominant optic atrophy treatment to provide analysis
After 39 days of this quarter the interest is at 33.0. Based on that we can calculate that during remaining 52 days it will total up to 77.0. Dravet syndrome treatment expected interest is significantly lower compared to previous quarter (-40.3%) and same quarter last year (-51.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 119 | 140 17.6% QoQ | 106 -24.3% QoQ | 13 -87.7% QoQ |
| 2020 | 93 -21.8% YoY 615.4% QoQ | 63 -55.0% YoY -32.3% QoQ | 164 54.7% YoY 160.3% QoQ | 46 253.8% YoY -72.0% QoQ |
| 2021 | 39 -58.1% YoY -15.2% QoQ | 62 -1.6% YoY 59.0% QoQ | 47 -71.3% YoY -24.2% QoQ | 66 43.5% YoY 40.4% QoQ |
| 2022 | 94 141.0% YoY 42.4% QoQ | 73 17.7% YoY -22.3% QoQ | 147 212.8% YoY 101.4% QoQ | 95 43.9% YoY -35.4% QoQ |
| 2023 | 158 68.1% YoY 66.3% QoQ | 61 -16.4% YoY -61.4% QoQ | 70 -52.4% YoY 14.8% QoQ | 129 35.8% YoY 84.3% QoQ |
| 2024 | 33 -79.1% YoY -74.4% QoQ | - | - | - |
The average 5 years interest of Dravet syndrome treatment was 6.97 per week. The last year interest of Dravet syndrome treatment compared to the last 5 years has changed by 5.45%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -16.95%.
There is not enough data for RNA-based medicines to provide analysis
There is not enough data for RNA-based medicines to provide correlation calculation
There is not enough data for RNA-based medicines to provide analysis
There is not enough data for severe genetic diseases treatment to provide analysis
There is not enough data for severe genetic diseases treatment to provide correlation calculation
There is not enough data for severe genetic diseases treatment to provide analysis